Introduction: Initiating Gla-300 has shown to improve treatment satisfaction in PwT2D in RCT and real-world studies. ATOS, a 12-month prospective observational global study showed that initiating Gla-300 in insulin-naïve PwT2D resulted in improved glycemic control and low hypoglycemia rates.
Methods: This post-hoc analysis evaluated meaningful improvements in Diabetes Treatment Satisfaction Questionnaire status (DTSQs) scores with glycemic parameters. Data was collected at baseline, months 3, 6 and 12, and based on distribution-based method (0.5 SD of baseline DTSQs score) for meaningfulness, percentage of responders was determined.
Results: Total, 3801 participants completed the questionnaire. At baseline, mean ± SD age was 57.7 ± 10.5 years, duration of diabetes was 10.2 ± 6.2 years and DTSQs total treatment satisfaction score 21.7 ± 7.4. Percentages of responders (improvement in DTSQs total score ≥4 points) were 60.2% at month 3 and 75.2% at month 12. A decrease in perceived frequency of hyper/hypoglycemia and higher reduction in mean HbA1c and FPG from baseline to month 12 were also observed for responders vs. non-responders (Table).
Conclusion: The majority of insulin naïve PwT2D initiating Gla-300 reported meaningful increase in treatment satisfaction and decrease in perceived frequency of hyper/hypoglycemia, associated with decreased HbA1c.
S.B. Harris: Consultant; Abbott. Research Support; Boehringer-Ingelheim. Consultant; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company, Novo Nordisk, Sanofi. Research Support; Novartis AG. Consultant; Bayer Inc. N. Khan: None. A. Tirosh: Advisory Panel; Novo Nordisk. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Sanofi, GlaxoSmithKline plc, Medtronic. Consultant; Radella Pharmaceuticals. J. Kesavadev: None. H. Vargas-Uricoechea: Speaker's Bureau; Abbott, Sanofi-Aventis U.S. A. Roborel de Climens: Stock/Shareholder; Sanofi. H. Baghous: Other Relationship; Sanofi, Novo Nordisk. F.J. Snoek: Advisory Panel; Abbott, Sanofi, Eli Lilly and Company, Roche Diabetes Care. M.N. Mabunay: None. N. Grulovic: Employee; Sanofi. V. Corp dit Genti: Employee; Sanofi. J. Msihid: Employee; Sanofi. Stock/Shareholder; Sanofi. G.R. Galstyan: None.
Sanofi
